Granted Patent B2

US 12,194,006 · App. 17/193,306 · Granted Jan 14, 2025

Inventor: Herriot Tabuteau (New York, NY)

Assignee: ANTECIP BIOVENTURES II LLC

A61K31/138A61K9/0053A61K31/137A61K31/485A61P25/24

Abstract

Claims (22)

1. A method of treating a neuropsychiatric condition, comprising administering a combination of an antidepressant and a dextromethorphan to a human being in need thereof; wherein the antidepressant is venlafaxine.

2. The method of claim 1 , wherein the neuropsychiatric condition is depression or agitation with Alzheimer's disease.

3. The method of claim 2 , wherein the combination is in a dosage form when administered, and the dosage form is orally administered daily to a human being suffering from depression or agitation with Alzheimer's disease; wherein the dosage form comprises dextromethorphan or a pharmaceutically acceptable salt thereof, and venlafaxine or a pharmaceutically acceptable salt thereof; wherein the dextromethorphan and the venlafaxine are the only therapeutically active agents in the dosage form; and wherein the human being is an extensive metabolizer of dextromethorphan.

4. The method of claim 3 , wherein the dosage form is orally administered for at least 8 consecutive days.

5. The method of claim 3 , wherein the depression is major depressive disorder.

6. The method of claim 3 , wherein the depression is treatment resistant depression.

7. The method of claim 3 , wherein the dosage form comprises about 30 mg to about 150 mg of the venlafaxine.

8. The method of claim 3 , wherein the dosage form is orally administered for at least 14 consecutive days.

9. The method of claim 3 , wherein the dosage form provides immediate release of the dextromethorphan.

10. The method of claim 3 , wherein the dosage form provides sustained release of the venlafaxine.

11. The method of claim 3 , wherein the dosage form contains about 20 mg to about 50 mg of the dextromethorphan.

12. The method of claim 3 , wherein the dosage form contains about 30 mg to about 60 mg of the dextromethorphan.

13. The method of claim 3 , wherein the dosage form contains about 40 mg to about 50 mg of the dextromethorphan.

14. The method of claim 3 , wherein the dosage form contains about 50 mg to about 70 mg of the dextromethorphan.

15. The method of claim 3 , wherein the dosage form contains about 70 mg to about 100 mg of the dextromethorphan.

16. The method of claim 3 , wherein the dosage form contains about 45 mg of a dextromethorphan salt.

17. The method of claim 3 , wherein the dextromethorphan comprises a deuterium-modified dextromethorphan.

18. The method of claim 3 , wherein the dosage form is a capsule, a tablet, or a solution.

19. The method of claim 3 , wherein a dextromethorphan plasma level is increased as compared to administering the same amount of dextromethorphan alone.

20. The method of claim 3 , wherein the human being is converted to a poor metabolizer of dextromethorphan.

21. The method of claim 3 , wherein the dosage form further comprises a pharmaceutically acceptable excipient.

22. The method of claim 3 , wherein the elimination half-life of dextromethorphan increases upon orally administering the dosage form.

Assignments (1)

Continuity (27)

References Cited (400)

Cited By (19)

US 12,239,642 US 12,357,697 US 12,370,154 US 12,377,091 US 12,390,428 US 12,433,884 US 12,447,138 US 12,472,155 US 12,472,156 US 12,472,174 US 12,478,622 US 12,544,345 US 12,564,587 US 12,569,479 US 12,576,078 US 12,599,576 US 12,653,795 US 12,661,408 US 12,678,506